Trials / Conditions / Leukemia, Myelocytic, Acute

Leukemia, Myelocytic, Acute

25 registered clinical trials studyying Leukemia, Myelocytic, Acute.

Status	Trial	Sponsor	Phase
Unknown	Infection and Tumour Antigen Cellular Therapy NCT02895412	University of Sydney	Phase 1
Completed	A Phase 1/2 Study of CPI-0610 With and Without Ruxolitinib in Patients With Hematologic and Myeloproliferative NCT02158858	Constellation Pharmaceuticals	Phase 1 / Phase 2
Completed	Comparison Between Two Dose Levels of Daunorubicin and Between One vs. Two Induction Cycles for Adult Patients NCT02140242	Technische Universität Dresden	Phase 3
Completed	A Phase I, Dose-finding Study of BEZ235 in Adult Patients With Relapsed or Refractory Acute Leukemia NCT01756118	Goethe University	Phase 1
Terminated	Reduced Intensity Regimen vs Myeloablative Regimen for Myeloid Leukemia or Myelodysplastic Syndrome (BMT CTN 0 NCT01339910	Medical College of Wisconsin	Phase 3
Terminated	Hematopoietic Stem Cell Transplantation (HSCT) Using CD34 Selected Mismatched Related Donor and One Umbilical NCT01050946	Medical College of Wisconsin	Phase 2
Completed	Sirolimus/Tacrolimus Versus Tacrolimus/Methotrexate for Preventing Graft-Versus-Host Disease (GVHD) (BMT CTN 0 NCT00406393	Medical College of Wisconsin	Phase 3
Terminated	Study of Parathyroid Hormone Following Sequential Cord Blood Transplantation From an Unrelated Donor NCT00393380	The Emmes Company, LLC	Phase 2
Terminated	A Phase II Study of Maintenance With Azacitidine in MDS Patients NCT00446303	Groupe Francophone des Myelodysplasies	Phase 2
Completed	Use of the MiCK Assay for Apoptosis in AML NCT00286845	Pierian Biosciences	—
Completed	Acute Myeloid Leukemia T Cell Depletion to Improve Transplants in Adults With Acute Myeloid Leukemia (BMT CTN NCT00201240	National Heart, Lung, and Blood Institute (NHLBI)	Phase 2
Unknown	Cladribine, Cytarabine and Idarubicin in Patients With Relapsed Acute Myelocytic Leukemia (AML) NCT00126321	University Hospital, Bonn	Phase 2
Terminated	Voriconazole or Placebo in the Prophylaxis of Lung Infiltrates in Patients Undergoing Induction Chemotherapy f NCT00152594	University of Cologne	Phase 3
Completed	Risk Adapted Treatment for Primary Acute Myeloid Leukemia (AML) NCT01723657	Grupo Cooperativo de Estudio y Tratamiento de las Leucemias Agudas y Mielodisplasias	Phase 2
Completed	Randomized Double Cord Blood Transplant Study NCT00067002	M.D. Anderson Cancer Center	Phase 2
Completed	Treatment of Patients With Newly Diagnosed Acute Myeloid Leukemia or Myelodysplasia NCT00136084	St. Jude Children's Research Hospital	Phase 3
Completed	Prophylaxis Trial of Posaconazole Versus Standard Azole Therapy for Neutropenic Patients (Study P01899) NCT00044486	Merck Sharp & Dohme LLC	Phase 3
Completed	Comparison of Two Treatments in Intermediate and High-risk Acute Promyelocytic Leukemia (APL) Patients to Asse NCT00962767	Wyeth is now a wholly owned subsidiary of Pfizer	Phase 3
Completed	Study Evaluating the Effect of Corticosteroids on Mylotarg® Infusion-Related Adverse Events in Patients With L NCT00304447	Wyeth is now a wholly owned subsidiary of Pfizer	Phase 4
Terminated	Anti-Leukemic Dendritic Cell Activated Donor Lymphocytes NCT00048100	M.D. Anderson Cancer Center	Phase 1
Unknown	AML Treatment in Untreated Adult Patients NCT00449319	Gruppo Italiano Malattie EMatologiche dell'Adulto	N/A
Completed	Risk-adapted Therapy for Adult Acute Myeloid Leukemia. NCT01716793	Grupo Cooperativo de Estudio y Tratamiento de las Leucemias Agudas y Mielodisplasias	Phase 2
Completed	Autologous Bone Marrow Transplantation in Acute Non-Lymphoblastic Leukemia During First or Subsequent Remissio NCT00186381	Stanford University	Phase 2
Completed	Multicenter Study of 9-Aminocamptothecin (9-AC) in Patients With Refractory Leukemia NCT00251368	Dana-Farber Cancer Institute	Phase 1
Completed	Trial to Reduce Alloimmunization to Platelets (TRAP) NCT00000589	National Heart, Lung, and Blood Institute (NHLBI)	Phase 3